With production facilities of UCB, Takeda, GSK, J&J, the Biotech Valley of Wallonia/Belgium is a major European hub for cell gene therapies, regenerative medicine, vaccine production, nuclear medicine, biomanufacturing and today, it’s a top choice for life sciences companies who want to expand their operations into Europe and for VC firms looking for great quality companies to invest in and collaborate with local investment funds. The region offers attractive incentives especially those for companies conducting R&D activities. We also represent an attractive portfolio of Belgian biotech companies who are looking for early-stage and mid-stage venture capital to fund their R&D operations in order to bring new life-saving therapy innovations to market. A notable transaction in 2025 was Esobiotec, acquired by Astra Zeneca for more than 1 billion $.